Press coverage about Aratana Therapeutics (NASDAQ:PETX) has trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aratana Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.7568183776025 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

PETX has been the topic of a number of recent analyst reports. Zacks Investment Research lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 18th. HC Wainwright set a $10.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 21st. Jefferies Group reiterated a “buy” rating and issued a $8.00 price objective on shares of Aratana Therapeutics in a research note on Friday, November 3rd. ValuEngine lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Finally, CL King initiated coverage on Aratana Therapeutics in a research note on Wednesday, December 27th. They issued a “neutral” rating on the stock. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $8.55.

Shares of Aratana Therapeutics (NASDAQ:PETX) traded down $0.14 on Friday, reaching $4.18. The company had a trading volume of 215,714 shares, compared to its average volume of 494,504. Aratana Therapeutics has a 1 year low of $3.91 and a 1 year high of $7.67. The company has a quick ratio of 3.08, a current ratio of 3.42 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $173.91, a price-to-earnings ratio of -2.88 and a beta of 3.06.

In related news, insider Craig A. Tooman sold 30,000 shares of the business’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $5.27, for a total transaction of $158,100.00. Following the transaction, the insider now directly owns 75,024 shares in the company, valued at $395,376.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Healthcare Master Fun Broadfin sold 116,516 shares of the business’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $6.53, for a total value of $760,849.48. The disclosure for this sale can be found here. Insiders have sold 1,056,399 shares of company stock worth $6,087,271 over the last 90 days. Corporate insiders own 5.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with's FREE daily email newsletter.